JESSICA PLUDRZYNSKI: Open Payments
NPI 1215500426 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,329 in 66 payments from 19 companies in 2025. Trend: 2023 $778 · 2024 $1,717 · 2025 $1,329
Food & beverage: $1,329
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $259 |
| AstraZeneca Pharmaceuticals LP | 6 | $226 |
| Novo Nordisk Inc | 11 | $220 |
| Lilly USA, LLC | 5 | $97 |
| GlaxoSmithKline, LLC. | 5 | $88 |
| Amgen Inc. | 3 | $59 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $56 |
| Abbott Laboratories | 3 | $53 |
| Tactile Systems Technology Inc | 1 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
Products named: FARXIGA, VRAYLAR, Wegovy, MOUNJARO, TRELEGY ELLIPTA, UBRELVY, QULIPTA, AIRSUPRA.
Industry payments across NY — which companies pay providers there.
